Jiannan Qiu

1.8k total citations · 2 hit papers
47 papers, 1.3k citations indexed

About

Jiannan Qiu is a scholar working on Epidemiology, Molecular Biology and Hepatology. According to data from OpenAlex, Jiannan Qiu has authored 47 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Epidemiology, 22 papers in Molecular Biology and 12 papers in Hepatology. Recurrent topics in Jiannan Qiu's work include Liver Disease Diagnosis and Treatment (25 papers), Diet, Metabolism, and Disease (7 papers) and Liver physiology and pathology (6 papers). Jiannan Qiu is often cited by papers focused on Liver Disease Diagnosis and Treatment (25 papers), Diet, Metabolism, and Disease (7 papers) and Liver physiology and pathology (6 papers). Jiannan Qiu collaborates with scholars based in China, Hong Kong and South Korea. Jiannan Qiu's co-authors include Xuehao Wang, Ling Lü, Runqiu Jiang, Yuanchang Hu, Jinhai Tang, Jianhua Rao, Shun Zhou, Liyong Pu, Yong Ni and Liren Zhang and has published in prestigious journals such as Hepatology, Gut and The FASEB Journal.

In The Last Decade

Jiannan Qiu

45 papers receiving 1.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation

2021 281 citations Jiannan Qiu, Xuehao Wang et al. profile →
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2

2022 152 citations Jianhua Rao, Hao Wang et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jiannan Qiu China	20	694	404	360	241	166	47	1.3k
Feixia Wang China	20	554 0.8×	397 1.0×	269 0.7×	278 1.2×	82 0.5×	42	1.2k
Claudia Paternostro Italy	17	475 0.7×	525 1.3×	289 0.8×	459 1.9×	237 1.4×	23	1.3k
Seonghwan Hwang South Korea	23	595 0.9×	878 2.2×	326 0.9×	321 1.3×	79 0.5×	51	1.7k
Xiaodong Ge United States	17	425 0.6×	631 1.6×	150 0.4×	432 1.8×	112 0.7×	40	1.5k
Chang Yeob Han South Korea	21	611 0.9×	414 1.0×	153 0.4×	160 0.7×	174 1.0×	35	1.2k
Yidong Yang China	18	635 0.9×	236 0.6×	483 1.3×	110 0.5×	126 0.8×	45	1.2k
Hanyong Sun China	13	413 0.6×	356 0.9×	136 0.4×	171 0.7×	210 1.3×	21	1.0k
Yi‐Qun Zhan China	18	748 1.1×	196 0.5×	146 0.4×	116 0.5×	117 0.7×	51	1.2k
Jingyun Luan China	24	739 1.1×	332 0.8×	150 0.4×	108 0.4×	217 1.3×	36	1.4k
Siwei Tan China	19	513 0.7×	227 0.6×	315 0.9×	117 0.5×	109 0.7×	42	1.1k

Countries citing papers authored by Jiannan Qiu

Since Specialization

Citations

This map shows the geographic impact of Jiannan Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiannan Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiannan Qiu more than expected).

Fields of papers citing papers by Jiannan Qiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiannan Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiannan Qiu. The network helps show where Jiannan Qiu may publish in the future.

Co-authorship network of co-authors of Jiannan Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Jiannan Qiu. A scholar is included among the top collaborators of Jiannan Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiannan Qiu. Jiannan Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Lin, Yuwei Jiang, Jiannan Qiu, et al.. (2025). Alisol B alleviates MASLD by activating liver autophagy and fatty acid oxidation via Ces2a. International Immunopharmacology. 157. 114768–114768. 1 indexed citations

Ding, Qinchao, Feiwei Cao, Rui Guo, et al.. (2025). Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease. Science Advances. 11(26). eadt6195–eadt6195. 2 indexed citations

Qiu, Jiannan, Yuan Fang, Yin Cao, et al.. (2025). SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy. Cell Death and Differentiation. 32(5). 959–972. 6 indexed citations

Ren, Guilin, et al.. (2025). Multi-omics joint analysis: Pachymic acid ameliorated non-alcoholic fatty liver disease by regulating gut microbiota. Food Research International. 209. 116178–116178.

Tian, Ling, Jie Hao, Jiannan Qiu, et al.. (2025). SFAs facilitates ceramide’s de novo synthesis via TLR4 and intensifies hepatocyte lipotoxicity. International Immunopharmacology. 147. 114020–114020. 2 indexed citations

Qiu, Jiannan, Fangying Xu, Yanyan Gao, et al.. (2025). Metabolic restoration: Rhubarb polysaccharides as a shield against non-alcoholic fatty liver disease. International Journal of Biological Macromolecules. 305(Pt 2). 141151–141151. 4 indexed citations

Ni, Ming, Jiannan Qiu, Peng Wu, et al.. (2024). Loss of macrophage TSC1 exacerbates sterile inflammatory liver injury through inhibiting the AKT/MST1/NRF2 signaling pathway. Cell Death and Disease. 15(2). 146–146. 5 indexed citations

Xu, Tiantian, Qinchao Ding, Feiwei Cao, et al.. (2024). The micro-743a-3p–GSTM1 pathway is an endogenous protective mechanism against alcohol-related liver disease in mice. Cellular & Molecular Biology Letters. 29(1). 35–35. 3 indexed citations

Guo, Jianan, Zhijun Liu, Jing Liu, et al.. (2024). Salvianolic acid A attenuates non-alcoholic fatty liver disease by regulating the AMPK-IGFBP1 pathway. Chemico-Biological Interactions. 400. 111162–111162. 6 indexed citations

10.

Tian, Lulu, Lin Chen, Jiannan Qiu, et al.. (2024). Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway. Phytomedicine. 131. 155776–155776. 7 indexed citations

11.

Qiu, Jiannan, Lin Chen, Guilin Ren, et al.. (2024). Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatment. Phytomedicine. 132. 155799–155799. 6 indexed citations

12.

Guo, Jianan, Yifei Le, Jing Liu, et al.. (2024). Astragaloside IV ameliorates cisplatin-induced liver injury by modulating ferroptosis-dependent pathways. Journal of Ethnopharmacology. 328. 118080–118080. 12 indexed citations

13.

Liu, Yuchen, Gang Wei, Fang‐Xin Wang, et al.. (2023). Design and Synthesis of Novel Indole Ethylamine Derivatives as a Lipid Metabolism Regulator Targeting PPARα/CPT1 in AML12 Cells. Molecules. 29(1). 12–12. 4 indexed citations

14.

Ma, Yue, Liuyi Hao, Qinchao Ding, et al.. (2023). 1-Methylnicotinamide promotes hepatic steatosis in mice: A potential mechanism in chronic alcohol-induced fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1868(4). 159286–159286. 1 indexed citations

15.

Qiu, Jiannan, Lin Chen, Ling Zhang, et al.. (2023). Xie Zhuo Tiao Zhi formula modulates intestinal microbiota and liver purine metabolism to suppress hepatic steatosis and pyroptosis in NAFLD therapy. Phytomedicine. 121. 155111–155111. 41 indexed citations

16.

Ma, Cheng, Yin Cao, Guang Zhang, et al.. (2023). Novel Nomograms Based on Gamma-Glutamyl Transpeptidase-to-Lymphocyte Ratio Predict Prognosis of Hepatocellular Carcinoma Patients After Hepatectomy. Journal of Hepatocellular Carcinoma. Volume 10. 217–230. 3 indexed citations

17.

Rao, Jianhua, Hao Wang, Ming Ni, et al.. (2022). FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2. Gut. 71(12). 2539–2550. 152 indexed citations breakdown →

18.

Wang, Peng, Ming Ni, Yizhu Tian, et al.. (2021). Myeloid Nrf2 deficiency aggravates non-alcoholic steatohepatitis progression by regulating YAP-mediated NLRP3 inflammasome signaling. iScience. 24(5). 102427–102427. 26 indexed citations

19.

Song, Wei, Qi Wang, Haoming Zhou, et al.. (2019). miR-455-3p Alleviates Hepatic Stellate Cell Activation and Liver Fibrosis by Suppressing HSF1 Expression. Molecular Therapy — Nucleic Acids. 16. 758–769. 61 indexed citations

20.

Wang, Qi, Song Wei, Haoming Zhou, et al.. (2019). Hyperglycemia exacerbates acetaminophen-induced acute liver injury by promoting liver-resident macrophage proinflammatory response via AMPK/PI3K/AKT-mediated oxidative stress. Cell Death Discovery. 5(1). 119–119. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact